Problems of Social Hygiene, Public Health and History of MedicineProblems of Social Hygiene, Public Health and History of Medicine0869-866X2412-2106Joint-Stock Company Chicot17510.32687/0869-866X-2019-27-5-796-802Научная статьяThe organizational aspects of early diagnostic of metabolic syndrome on the basis of implementation of new genetic, cellular and bio-informational technologiesKhabrievR. U.-KakorinaE. P.-KuzminaL. P.-FishmanB. B.Fishman@mxc.ruProzorovaI. V.-RaffS. A.-AbdulinA. A.-IukhnoM. V.-N. A. Semashko National Research Institute of Public HealthThe Federal State Autonomous Educational Institution of Higher Education “The I. M. Sechenov First Moscow State Medical University” of Minzdrav of RussiaThe Federal State Budget Scientific Institution “The N. F. Izmerov Research Institute of occupational medicine” of the Russian Academy of SciencesThe Federal State Budget Educational Institution of Higher Education “The Yaroslav the Sage Novgorod State University”The Federal State Budget Educational Institution of Higher Education “The Kuban State Medical University”1512201927579680206042021Copyright © 2019,2019The characteristic feature of molecular medicine as medicine based on molecular structure of human genome data, is its individual character. It is focused on correcting pathological process in specific individual considering unique characteristics of its genome. The other most important feature is its expressed preventive direction. The complete genome information can be obtained well before the onset of disease. The appropriate preventive measures can completely eliminate or significantly prevent development of severe disease. The establishment of gene network of every multi-factorial disease, identification of central genes and genes-modifiers in it, analysis of association of their alleles with disease, development on this basis of set of preventive measures for specific patient constitute conceptual and methodological basis of predictive medicine.As a result of the examination, information can be obtained concerning particular risk of disease development. The physician, considering the results of molecular genetic analysis, elaborates tactics of pathogenetically justified preventive therapy, i.e. corrects congenital metabolic defect.metabolic syndromepr-clinical genome diagnosticsметаболический синдромдоклиническая геномная диагностика1.Samson S. L., Garber A. J. Metabolic syndrome. Endocrinol. Metab. Clin. North. Am. 2014;43(1):1-23.2.Kaur J. A comprehensive Review on Metabolic Syndrome. Cardiol. Res. Pract. 2014. doi: 10.1155/2014/9431623.Procopciuc L., Popescu T., Jebeleanu G., Pop D., Zdrenghea D. Essential Arterial Hypertesion and Polymorphismof Angiotensinogen M235T Gene. J. Cell. Mol. Med. 2002;6(2):245-50.4.Azizi M., Hallouin M.-C., Jeunemaitre X., Guyene T. T., Ménard J. Influence of the M235T Polymorphism of Human Angiotensinogen (AGT) on Plasma AGT and Renin Concentrations After Ethinylestradiol Administration. J. Clin. Endocrinol. Metab. 2000;85(11):4331-7.5.Zhou A., Carrell R. W., Murphy M. P., Wei Z., Yan Y., Stanley P. L. D., Stein P. E., Broughton Pipkin F., Read R. J. A Redox Switch in Angiotensinogen Modulates Angiotensin Release. Nature. 2010;468(7320):108-11.6.Danesh J. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294(14):1799-809.7.Mannila M. N. Contribution of haplotypes across the fibrinogen gene cluster to variation in risk of myocardial infarction. Thromb. Haemost. 2005;93(3):570-7.8.Casas J. P., Hingorani A. D., Bautista L. E., Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch. Neurol. 2004;61(11):1652-61.9.Kathiresan S. Common genetic variation in five thrombosis genes and relations to plasma hemostatic protein level and cardiovascular disease risk. Arterioscler. Thromb. Vasc. Biol. 2006;26(6):1405-12.10.Lusis A. J., Fogelman A. M., Fonarow G. C. Genetic basis of atherosclerosis. II. Clinical implications. Circulation. 2004;110:2066-71.11.Богова О. Т., Чукаева И. И. Инфаркт миокарда. Воспаление и прогноз. Российский кардиологический журнал. 2003;(4):18-23.12.Gabriel A. S., Ahnve S., Wretlind B., Martinsson A. IL-6 and IL-1 receptor antagonist in stable angina pectoris and relation ofIL-6 to clinical findings in acute myocardial infarction. J. Intern. Med. 2000;248:61-6.13.Crea F., Biasucci L. M., Buffon A., Liuzzo G., Monaco C., Caligiuri G., Kol A., Sperti G., Cianflone D., Maseri A. Role of inflammation in the pathogenesis of unstable coronary artery disease. Am. J. Cardiol. 1997;80:10-6.14.Brull D. J., Montgomery H. E., Sanders J., Dhamrait S., Luong L., Rumley A., Lowe G. D. O., Humphries S. E. Atherosclerosis and Lipoproteins Interleukin-6 Gene -174 G > C and -572 G > C Promoter Polymorphisms Are Strong Predictors of Plasma Interleukin-6 Levels After Coronary Artery Bypass Surgery. Arterioscler. Thromb. Vasc. Biol. 2001;21:1458-63.15.Henningsson S., Håkansson A., Westberg L., Baghaei F., Rosmond R., Holm G., Ekman A., Nissbrandt H., Eriksson E. Interleukin-6 Gene Polymorphism -174 G/C Influences Plasma Lipid Levels in Women. Obesity. 2006;14(11):1868-73.16.Humphries S. E., Luong L. A., Ogg M. S., Hawe E., Miller G. J. The interleukin-6 - 174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur. Heart J. 2001;22:2243-52.17.Basso F., Lowe G. D. O., Rumley A., McMahon A. D., Humphries S. E. Interleukin-6 - 174 G > C Polymorphism and Risk of Coronary Heart Disease in West of Scotland Coronary Prevention Study (WOSCOPS), on behalf of the WOSCOPS Group. Arterioscler. Thromb. Vasc. Biol. 2002;22:599-604.